The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.
The VT Reedle Shot, a skincare product using silica spicules, is discussed as a potential at-home alternative to microneedling for hair regrowth. It is suggested that different intensities may aid in hairline regrowth.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.
Tocotrienols are being discussed as a potential treatment for hair regrowth, but users report no noticeable effects after several months of use. Some users are combining tocotrienols with other treatments like pumpkin seed oil and peppermint and rosemary oil.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
The conversation is about whether taking 0.5mg of finasteride daily is as effective as 1mg for hair regrowth and if there are long-term studies supporting the lower dose. The user is considering the lower dose to save money and reduce concerns about side effects.
A user discovered they have naturally low DHT levels and is concerned about taking finasteride, which could further lower these levels. They are seeking advice on whether to proceed with the treatment given their hormone levels are within the normal range.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The user started a consistent hair loss treatment routine in January, using finasteride, minoxidil, red light therapy, micro-needling, vitamins, and specific shampoos. They noticed potential progress after 11 weeks and plan to update in a few months.
A 19-year-old is unsure if their hair is receding or just maturing and is seeking opinions before starting treatments like Minoxidil, finasteride, or RU58841. They shared recent and past photos to compare changes over a few months.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
The user has been using finasteride and dutasteride for hair loss but is experiencing low energy and motivation, possibly due to high prolactin levels. Despite treatment, hairline recession continues, and the user is considering the impact of low DHT levels on overall health and energy.
Cyproterone Acetate stopped hair loss and led to regrowth on the temples for a transgender individual, which is considered a good sign. Unlike Minoxidil and Finasteride, which can cause initial shedding, Cyproterone did not cause shedding.
The user is experiencing potential hair regrowth after 3 months of using 0.5mg Dutasteride, 2.5mg Minoxidil, and 2% Ketoconazole shampoo, along with supplements like pumpkin seed oil and vitamin D. They notice tiny hairs on their scalp and seek opinions on whether this indicates regrowth.
The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.
The conversation discusses a 13-month hair loss treatment update using dutasteride, minoxidil, nizoral, and a 1.5mm derma roller, with the original poster reporting no side effects and some improvement in hair thickness. Participants request before-and-after pictures with consistent hairstyles to better assess the treatment's effectiveness.
PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.
A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.
The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.
User reported initial hair regrowth with 0.25 mg finasteride taken four times a week, experiencing a second shedding phase, and no side effects. They also mentioned using RU58841 without success and plan to stop after a year.
The user got blood work to check hormone levels before starting Finasteride for hair loss and is seeking advice on interpreting the results. They are considering hormone levels in relation to potential side effects of Finasteride.
Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.